The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent BTK inhibitors with fewer adverse events in mantle cell lymphoma.
Erratum: Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance Retrospective, ...
Testing to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and factors ...
Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non–Small Cell Lung Cancer in Brazil Among 273 patients, cCRT and sCRT were administered with equal ...
New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs. Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev ...